Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma

Jaewhan Song

Clin Mol Hepatol. 2020;26(4):484-486. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0220

View: 5722 Download: 133 Web of Science: 7 Crossref: 7

Long-term prognosis and management of hepatocellular carcinoma after curative treatment

Naoshi Nishida

Clin Mol Hepatol. 2020;26(4):480-483. Published online September 21, 2020

DOI: https://doi.org/10.3350/cmh.2020.0208

View: 5067 Download: 97 Web of Science: 11 Crossref: 11

Original Article

Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging

Sunyoung Lee, Seung-seob Kim, Dong ryul Chang, Hyerim Kim, Myeong-Jin Kim

Clin Mol Hepatol. 2020;26(3):340-351. Published online June 4, 2020

DOI: https://doi.org/10.3350/cmh.2020.0004

View: 8443 Download: 205 Web of Science: 41 Crossref: 45

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment

Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim

Clin Mol Hepatol. 2020;26(3):328-339. Published online May 28, 2020

DOI: https://doi.org/10.3350/cmh.2019.0049n

View: 8295 Download: 336 Web of Science: 30 Crossref: 30

Editorial

Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?

So Yeon Kim

Clin Mol Hepatol. 2020;26(3):309-311. Published online June 15, 2020

DOI: https://doi.org/10.3350/cmh.2020.0061

View: 4699 Download: 99 Web of Science: 5 Crossref: 5

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

Sojung Han, Do Young Kim

Clin Mol Hepatol. 2020;26(3):305-308. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0096

View: 4162 Download: 108 Web of Science: 5 Crossref: 5

Letter to the Editor

Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma

Hwi Young Kim, Jean-François Dufour

Clin Mol Hepatol. 2020;26(2):238-239. Published online March 18, 2020

DOI: https://doi.org/10.3350/cmh.2020.0051

View: 3850 Download: 61 Web of Science: 1 Crossref: 1

Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: Up to now and next steps

Rodrigo Cañada Trofo Surjan, Elizabeth Santana dos Santos, Sergio do Prado Silveira, Fabio Ferrari Makdissi, Marcel Autran Cesar Machado

Clin Mol Hepatol. 2020;26(2):231-232. Published online November 4, 2019

DOI: https://doi.org/10.3350/cmh.2019.0084

View: 4020 Download: 85 Web of Science: 3 Crossref: 3

Original Article

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma

Rahul Kumar, Boon-Bee George Goh, Jia-Wen Kam, Pik-Eu Chang, Chee-Kiat Tan

Clin Mol Hepatol. 2020;26(2):196-208. Published online January 9, 2020

DOI: https://doi.org/10.3350/cmh.2019.0012

View: 7984 Download: 269 Web of Science: 14 Crossref: 14

Editorial

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?

Ju Hyun Shim

Clin Mol Hepatol. 2020;26(2):183-184. Published online March 12, 2020

DOI: https://doi.org/10.3350/cmh.2020.0042

View: 4173 Download: 111 Web of Science: 6 Crossref: 6

Review

Switching to systemic therapy after locoregional treatment failure: Definition and best timing

Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato

Clin Mol Hepatol. 2020;26(2):155-162. Published online January 15, 2020

DOI: https://doi.org/10.3350/cmh.2019.0021n

View: 9721 Download: 408 Web of Science: 41 Crossref: 38

Letter to the Editor

Hyperammonemic encephalopathy: An unusual presentation of fibrolamellar hepatocellular carcinoma

Nimish Thakral, Douglas A. Simonetto

Clin Mol Hepatol. 2020;26(1):74-77. Published online August 16, 2019

DOI: https://doi.org/10.3350/cmh.2018.0042

View: 6472 Download: 136 Web of Science: 7 Crossref: 10

Original Article

Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard

Jamak Modaresi Esfeh, Kaveh Hajifathalian, Kianoush Ansari-Gilani

Clin Mol Hepatol. 2020;26(1):54-59. Published online November 15, 2019

DOI: https://doi.org/10.3350/cmh.2019.0039

View: 8157 Download: 188 Web of Science: 43 Crossref: 44

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti

Clin Mol Hepatol. 2020;26(1):45-53. Published online September 30, 2019

DOI: https://doi.org/10.3350/cmh.2019.0031

View: 7612 Download: 250 Web of Science: 17 Crossref: 14

Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection

Hye Soo Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Young Nyun Park, Dai Hoon Han, Kyung Sik Kim, Jin Sub Choi, Gi Hong Choi, Hyon-Suk Kim

Clin Mol Hepatol. 2020;26(1):33-44. Published online June 27, 2019

DOI: https://doi.org/10.3350/cmh.2018.0073

View: 5810 Download: 183 Web of Science: 18 Crossref: 15

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea

Jae Seung Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jin Sil Seong, Kwang-Hyub Han, Do Young Kim

Clin Mol Hepatol. 2020;26(1):24-32. Published online May 20, 2019

DOI: https://doi.org/10.3350/cmh.2018.0065

View: 9588 Download: 299 Web of Science: 29 Crossref: 29

Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B

Haneulsaem Shin, Yeon Woo Jung, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Yeun-Yoon Kim, Jin-Young Choi, Seung Up Kim

Clin Mol Hepatol. 2019;25(4):390-399. Published online May 31, 2019

DOI: https://doi.org/10.3350/cmh.2018.0103

View: 6089 Download: 145 Web of Science: 19 Crossref: 19

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients

Kei Moriya, Tadashi Namisaki, Shinya Sato, Masanori Furukawa, Akitoshi Douhara, Hideto Kawaratani, Kosuke Kaji, Naotaka Shimozato, Yasuhiko Sawada, Soichiro Saikawa, Hiroaki Takaya, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji

Clin Mol Hepatol. 2019;25(4):381-389. Published online August 13, 2019

DOI: https://doi.org/10.3350/cmh.2019.0037

View: 5465 Download: 136 Web of Science: 12 Crossref: 10

Review

Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?

Keun Soo Ahn, Koo Jeong Kang

Clin Mol Hepatol. 2019;25(4):354-359. Published online April 22, 2019

DOI: https://doi.org/10.3350/cmh.2018.0096

View: 7569 Download: 358 Web of Science: 41 Crossref: 39

Ultraselective conventional transarterial chemoembolization: When and how?

Shiro Miyayama

Clin Mol Hepatol. 2019;25(4):344-353. Published online April 26, 2019

DOI: https://doi.org/10.3350/cmh.2019.0016

View: 11024 Download: 548 Web of Science: 28 Crossref: 31

Detect or not to detect very early stage hepatocellular carcinoma? The western perspective

Ju Dong Yang

Clin Mol Hepatol. 2019;25(4):335-343. Published online March 29, 2019

DOI: https://doi.org/10.3350/cmh.2019.0010

View: 10613 Download: 234 Web of Science: 38 Crossref: 38

Original Article

Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio

Linda Wong, Kliment Bozhilov, Brenda Hernandez, Sandi Kwee, Owen Chan, Luke Ellis, Loic LeMarchand

Clin Mol Hepatol. 2019;25(3):305-316. Published online April 19, 2019

DOI: https://doi.org/10.3350/cmh.2019.0004

View: 6229 Download: 167 Web of Science: 22 Crossref: 20

Review

Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?

Ibrahim A. Hanouneh, Naim Alkhouri, Amit G. Singal

Clin Mol Hepatol. 2019;25(3):264-269. Published online March 4, 2019

DOI: https://doi.org/10.3350/cmh.2019.1001

View: 9576 Download: 324 Web of Science: 47 Crossref: 47

Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update

Tae-Hyung Kim, So Yeon Kim, An Tang, Jeong Min Lee

Clin Mol Hepatol. 2019;25(3):245-263. Published online February 14, 2019

DOI: https://doi.org/10.3350/cmh.2018.0090

View: 18406 Download: 1,035 Web of Science: 140 Crossref: 148

Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers

Yeun-Yoon Kim, Mi-Suk Park, Khalid Suliman Aljoqiman, Jin-Young Choi, Myeong-Jin Kim

Clin Mol Hepatol. 2019;25(3):223-233. Published online January 21, 2019

DOI: https://doi.org/10.3350/cmh.2018.0107

View: 10236 Download: 407 Web of Science: 27 Crossref: 29

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2019;25(2):168-171. Published online February 11, 2019

DOI: https://doi.org/10.3350/cmh.2018.1014

View: 5794 Download: 179 Web of Science: 4 Crossref: 5

Original Article

Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization

Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Teerha Piratvisuth

Clin Mol Hepatol. 2019;25(1):74-85. Published online February 28, 2019

DOI: https://doi.org/10.3350/cmh.2018.0072

View: 7153 Download: 202 Web of Science: 20 Crossref: 22

Review

Radiomics and radiogenomics of primary liver cancers

Woo Kyoung Jeong, Neema Jamshidi, Ely Richard Felker, Steven Satish Raman, David Shinkuo Lu

Clin Mol Hepatol. 2019;25(1):21-29. Published online November 16, 2018

DOI: https://doi.org/10.3350/cmh.2018.1007

View: 12141 Download: 401 Web of Science: 43 Crossref: 44

Pathologic differential diagnosis of metastatic carcinoma in the liver

Jeong Hwan Park, Jung Ho Kim

Clin Mol Hepatol. 2019;25(1):12-20. Published online October 5, 2018

DOI: https://doi.org/10.3350/cmh.2018.0067

View: 24330 Download: 1,097 Web of Science: 37 Crossref: 40

Case Report

Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: case report with 8-year follow up

Hojung Jung, Byung Ik Kim, Yong Kyun Cho, Woo Kyu Jeon, Hong Joo Kim, Hyun Pyo Hong

Clin Mol Hepatol. 2018;24(4):424-429. Published online November 14, 2017

DOI: https://doi.org/10.3350/cmh.2017.0032

View: 9716 Download: 169 Crossref: 1

Viewed By 5322	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5269	MAFLD: How is it different from NAFLD?
Viewed By 5159	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3873	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3815	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Hepatic neoplasm